Parsabiv and Gastroesophageal reflux disease - a phase IV clinical study of FDA data

Summary:

Gastroesophageal reflux disease is reported as a side effect among people who take Parsabiv (etelcalcetide), especially for people who are female, 60+ old, have been taking the drug for < 1 month also take Fosrenol, and have Hyperparathyroidism secondary.

The phase IV clinical study analyzes which people have Gastroesophageal reflux disease when taking Parsabiv. It is created by eHealthMe based on reports of 3,712 people who have side effects when taking Parsabiv from the FDA, and is updated regularly.

What is Parsabiv?

Parsabiv has active ingredients of etelcalcetide. eHealthMe is studying from 3,712 Parsabiv users. Check the latest studies of Parsabiv.

What is Gastroesophageal reflux disease?

Gastroesophageal reflux disease (a condition in which stomach contents leak backward from the stomach into the oesophagus) is found to be associated with 2,396 drugs and 3,490 conditions by eHealthMe. Check the latest studies of Gastroesophageal reflux disease.

On Apr, 29, 2026

3,712 people reported to have side effects when taking Parsabiv.
Among them, 27 people (0.73%) have Gastroesophageal reflux disease.

Could Parsabiv cause Gastroesophageal reflux disease?

Among these 27 people:

How long have people been on Parsabiv when they have Gastroesophageal reflux disease? *

What is the gender of people who have Gastroesophageal reflux disease when taking Parsabiv? *

female: 62.96 %
male: 37.04 %

What is the age of people who have Gastroesophageal reflux disease when taking Parsabiv? *

What are other drugs people take besides Parsabiv? *

Rocaltrol: 10 people, 37.04%
Fosrenol: 10 people, 37.04%
Sensipar: 5 people, 18.52%
Lanthanum Carbonate: 3 people, 11.11%
Olmetec: 2 people, 7.41%
Mircera: 2 people, 7.41%
Heparin: 2 people, 7.41%
Crestor: 2 people, 7.41%
Cinacalcet Hydrochloride: 2 people, 7.41%
Calcium Carbonate: 2 people, 7.41%

What are other side effects people have besides Gastroesophageal reflux disease? *

Shunt Stenosis (narrowing of shunt): 13 people, 48.15%
Nausea And Vomiting: 12 people, 44.44%
Nasopharyngitis (inflammation of the nasopharynx): 7 people, 25.93%
Rashes (redness): 6 people, 22.22%
Arrhythmias (irregular heartbeat): 5 people, 18.52%
Anorectal Abscess: 5 people, 18.52%
Conjunctivitis Allergic (inflammation of the conjunctiva due to allergy): 5 people, 18.52%
Contrast Media Allergy (reaction associated with the use of intravenous contrast material during radiology): 5 people, 18.52%
Retinal Haemorrhage (bleeding from retina): 5 people, 18.52%
Head Injury: 5 people, 18.52%

What are the existing conditions these people have? *

Hyperparathyroidism Secondary (an abnormally high concentration of parathyroid hormone in the blood, resulting in weakening of the bones through loss of calcium-secondary): 21 people, 77.78%
Diabetes: 5 people, 18.52%
Anaemia (lack of blood): 2 people, 7.41%
Peripheral Arterial Occlusive Disease (reproducible ischemic muscle pain): 1 person, 3.70%
Hyperuricaemia (level of uric acid in the blood that is abnormally high): 1 person, 3.70%
Hyperphosphataemia (electrolyte disturbance in which there is an abnormally elevated level of phosphate in the blood): 1 person, 3.70%
Blood Parathyroid Hormone Increased: 1 person, 3.70%

* Approximation only. Some reports may have incomplete information.

Do you take Parsabiv and have Gastroesophageal reflux disease?

- Check whether Gastroesophageal reflux disease is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Parsabiv:

Parsabiv (3,712 reports)

Browse all side effects of Parsabiv:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Gastroesophageal reflux disease:

Gastroesophageal reflux disease (2,396 drugs)

Browse all the conditions that are associated with Gastroesophageal reflux disease:

Gastroesophageal reflux disease (3,490 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on etelcalcetide (the active ingredients of Parsabiv) and Parsabiv (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.